Cindy L Schwartz1, Lu Chen2, Kathleen McCarten3, Suzanne Wolden4, Louis S Constine5, Robert E Hutchison6, Pedro A de Alarcon7, Frank G Keller8, Kara M Kelly9, Tanya A Trippet4, Stephan D Voss10, Debra L Friedman11. 1. Division of Pediatrics, UT MD Anderson Cancer Center, Houston, Texas. 2. Children's Oncology Group, Monrovia, California. 3. Department of Radiology R.I. Hospital, Warren Alpert Medical School, Providence, Rhode Island. 4. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, NY, New York. 5. Department of Radiation Oncology, University of Rochester, Rochester, New York. 6. Department of Pathology, S.U.N.Y. Upstate Medical University, Syracuse, New York. 7. Department of Pediatrics, University of Illinois College of Medicine, Peoria, Illinois. 8. Department of Pediatrics, Emory University, Atlanta, Georgia. 9. Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, New York. 10. Department of Radiology, Boston Children's Hospital, Boston, Massachusetts. 11. Vanderbilt University School of Medicine, Ingram Cancer Center, Nashville, Tennessee.
Abstract
BACKGROUND: Early response to initial chemotherapy in Hodgkin lymphoma (HL) measured by computed tomography (CT) and/or positron emission tomography (PET) after two to three cycles of chemotherapy may inform therapeutic decisions. Risk stratification at diagnosis could, however, allow earlier and potentially more efficacious treatment modifications. PATIENTS AND METHODS: We developed a predictive model for event-free survival (EFS) in pediatric/adolescent HL using clinical data known at diagnosis from 1103 intermediate-risk HL patients treated on Children's Oncology Group protocol AHOD0031 with doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide (ABVE-PC) chemotherapy and radiation. Independent predictors of EFS were identified and used to develop and validate a prognostic score (Childhood Hodgkin International Prognostic Score [CHIPS]). A training cohort was randomly selected to include approximately half of the overall cohort, with the remainder forming the validation cohort. RESULTS: Stage 4 disease, large mediastinal mass, albumin (<3.5), and fever were independent predictors of EFS that were each assigned one point in the CHIPS. Four-year EFS was 93.1% for patients with CHIPS = 0, 88.5% for patients with CHIPS = 1, 77.6% for patients with CHIPS = 2, and 69.2% for patients with CHIPS = 3. CONCLUSIONS: CHIPS was highly predictive of EFS, identifying a subset (with CHIPS 2 or 3) that comprises 27% of intermediate-risk patients who have a 4-year EFS of <80% and who may benefit from early therapeutic augmentation. Furthermore, CHIPS identified higher risk patients who were not identified by early PET or CT response. CHIPS is a robust and inexpensive approach to predicting risk in patients with intermediate-risk HL that may improve ability to tailor therapy to risk factors known at diagnosis.
BACKGROUND: Early response to initial chemotherapy in Hodgkin lymphoma (HL) measured by computed tomography (CT) and/or positron emission tomography (PET) after two to three cycles of chemotherapy may inform therapeutic decisions. Risk stratification at diagnosis could, however, allow earlier and potentially more efficacious treatment modifications. PATIENTS AND METHODS: We developed a predictive model for event-free survival (EFS) in pediatric/adolescent HL using clinical data known at diagnosis from 1103 intermediate-risk HL patients treated on Children's Oncology Group protocol AHOD0031 with doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide (ABVE-PC) chemotherapy and radiation. Independent predictors of EFS were identified and used to develop and validate a prognostic score (Childhood Hodgkin International Prognostic Score [CHIPS]). A training cohort was randomly selected to include approximately half of the overall cohort, with the remainder forming the validation cohort. RESULTS: Stage 4 disease, large mediastinal mass, albumin (<3.5), and fever were independent predictors of EFS that were each assigned one point in the CHIPS. Four-year EFS was 93.1% for patients with CHIPS = 0, 88.5% for patients with CHIPS = 1, 77.6% for patients with CHIPS = 2, and 69.2% for patients with CHIPS = 3. CONCLUSIONS: CHIPS was highly predictive of EFS, identifying a subset (with CHIPS 2 or 3) that comprises 27% of intermediate-risk patients who have a 4-year EFS of <80% and who may benefit from early therapeutic augmentation. Furthermore, CHIPS identified higher risk patients who were not identified by early PET or CT response. CHIPS is a robust and inexpensive approach to predicting risk in patients with intermediate-risk HL that may improve ability to tailor therapy to risk factors known at diagnosis.
Authors: Monika L Metzger; Howard J Weinstein; Melissa M Hudson; Amy L Billett; Eric C Larsen; Alison Friedmann; Scott C Howard; Sarah S Donaldson; Matthew J Krasin; Larry E Kun; Karen J Marcus; Torunn I Yock; Nancy Tarbell; Catherine A Billups; Jianrong Wu; Michael P Link Journal: JAMA Date: 2012-06-27 Impact factor: 56.272
Authors: Debra L Friedman; Lu Chen; Suzanne Wolden; Allen Buxton; Kathleen McCarten; Thomas J FitzGerald; Sandra Kessel; Pedro A De Alarcon; Allen R Chen; Nathan Kobrinsky; Peter Ehrlich; Robert E Hutchison; Louis S Constine; Cindy L Schwartz Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544
Authors: Günther Schellong; Marianne Riepenhausen; Christian Bruch; Stefan Kotthoff; Johannes Vogt; Tobias Bölling; Karin Dieckmann; Richard Pötter; Achim Heinecke; Jürgen Brämswig; Wolfgang Dörffel Journal: Pediatr Blood Cancer Date: 2010-12-01 Impact factor: 3.167
Authors: James B Nachman; Richard Sposto; Philip Herzog; Gerald S Gilchrist; Suzanne L Wolden; John Thomson; Marshall E Kadin; Paul Pattengale; P Charlton Davis; Raymond J Hutchinson; Keith White Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: Anas Younes; Joseph M Connors; Steven I Park; Michelle Fanale; Megan M O'Meara; Naomi N Hunder; Dirk Huebner; Stephen M Ansell Journal: Lancet Oncol Date: 2013-11-15 Impact factor: 41.316
Authors: Ann C Mertens; Yutaka Yasui; Yan Liu; Marilyn Stovall; Ray Hutchinson; Jill Ginsberg; Charles Sklar; Leslie L Robison Journal: Cancer Date: 2002-12-01 Impact factor: 6.921
Authors: Lianna J Marks; Kathleen M McCarten; Qinglin Pei; Debra L Friedman; Cindy L Schwartz; Kara M Kelly Journal: Blood Date: 2018-07-30 Impact factor: 22.113
Authors: Lisa Giulino-Roth; Tara O'Donohue; Zhengming Chen; Tanya M Trippett; Elizabeth Klein; Nancy A Kernan; Rachel Kobos; Susan E Prockop; Andromachi Scaradavou; Neerav Shukla; Peter G Steinherz; Alison J Moskowitz; Craig H Moskowitz; Farid Boulad Journal: Leuk Lymphoma Date: 2017-11-29
Authors: Thomas Williams McLean; Ryan Michael Stewart; Thomas Patrick Curley; Mark Young Dewsnup; Sydney Gillian Thomas; Thomas Bennett Russell; Janet Austin Tooze Journal: Pediatr Blood Cancer Date: 2019-11-17 Impact factor: 3.167
Authors: Rebecca L Johnston; Anja Mottok; Fong Chun Chan; Aixiang Jiang; Arjan Diepstra; Lydia Visser; Adèle Telenius; Randy D Gascoyne; Debra L Friedman; Cindy L Schwartz; Kara M Kelly; David W Scott; Terzah M Horton; Christian Steidl Journal: Blood Date: 2022-02-10 Impact factor: 25.476
Authors: Sachin R Jhawar; Zorimar Rivera-Núñez; Richard Drachtman; Peter D Cole; Bradford S Hoppe; Rahul R Parikh Journal: JAMA Oncol Date: 2019-05-01 Impact factor: 31.777
Authors: Kathleen M McCarten; Monika L Metzger; Richard A Drachtman; Qinglin Pei; Debra L Friedman; Cindy L Schwartz; Kara M Kelly Journal: Pediatr Radiol Date: 2018-07-16